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A B S T R A C T
The regulation of metabolic processes by the Indy (I′m Not Dead Yet) (SLC13A5/NaCT) gene was revealed
through studies in Drosophila melanogaster and Caenorhabditis elegans. Reducing the expression of Indy in these
species extended their life span by a mechanism resembling caloric restriction, without reducing food intake. In
D. melanogaster, mutating the Indy gene reduced body fat content, insulin-like proteins and reactive oxygen
species production. Subsequent studies indicated that Indy encodes a citrate transporter located on the cell
plasma membrane. The transporter is highly expressed in the mammalian liver. We generated a mammalian
knock out model deleting the mammalian homolog mIndy (SLC13A5). The knock out animals were protected
from HFD induced obesity, fatty liver and insulin resistance. Moreover, we have shown that inducible and liver
selective knock down of mIndy protects against the development of fatty liver and insulin resistance and that
obese humans with type 2 diabetes and non-alcoholic fatty liver disease have increased levels of mIndy.
Therefore, the transporter mINDY (NaCT) has been proposed to be an ‘ideal target for the treatment of metabolic
disease’. A small molecule inhibitor of the mINDY transporter has been generated, normalizing glucose levels
and reducing fatty liver in a model of diet induced obese mice. Taken together, studies from lower organisms,
mammals and humans suggest that mINDY (NaCT) is an attractive target for the treatment of metabolic disease.
1. Introduction
The non-electrogenic solute transporter INDY – an acronym for I′m
Not Dead Yet – carries di- and tricarboxylates across the plasma
membrane in D. melanogaster (Inoue, Zhuang, & Ganapathy, 2002). In
D. melanogaster and C. elegans, reduced expression of Indy and its
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homolog CeNac2 promoted longevity in a manner akin to caloric re-
striction, one of the most reliable interventions prolonging healthy life
span over a wide range of species (Anderson & Weindruch, 2012;
Rogina, Reenan, Nilsen, & Helfand, 2000). In mammals, mIndy encodes
the sodium-coupled citrate transporter NaCT, which shares the highest
sequence and functional similarity with D. melanogaster Indy. mINDY
knockout mice are protected from obesity and insulin resistance asso-
ciated with a high fat diet or with normal aging (Birkenfeld et al.,
2011). The eﬀect is mediated by a switch in mitochondrial metabolism
and reduced hepatic lipid generation. These promising ﬁndings led to
the development of new pharmacological approaches targeting mINDY
as a candidate in the context of metabolic diseases like insulin re-
sistance and type 2 diabetes.
In this review, we summarize the role of mIndy in metabolic control
in diﬀerent cells and tissues and describe the most recent advances on
structure, expression and function of the dimer. We present a previously
unpublished three dimensional structure of mINDY/NaCT. In addition,
we discuss new pharmacological approaches using mINDY/NaCT as a
target structure.
2. INDY — molecular structure and function
In D. melanogaster, Indy is a cation independent, electroneutral
transmembrane transporter carrying di- and tricarboxylates across the
plasma membrane, whereas the mammalian INDY transporter is cation
dependent (Inoue, Zhuang, & Ganapathy, 2002; Rogina, 2017). mINDY
belongs to the SLC13 protein family, consisting of sodium-coupled di-
and tri-carboxylate/sulfate transporters (Markovich & Murer, 2004;
Willmes & Birkenfeld, 2013). The SLC13 family comprises ﬁve genes
Slc13a1–Slc13a5; encoding multi-spanning transporters with 8–13
transmembrane α-helices ﬂanked by an intracellular N-terminus and an
extracellular C-terminus, containing putative consensus glycosylation
sites (Markovich, 2008; Markovich & Murer, 2004; Willmes &
Birkenfeld, 2013). Slc13a1–5 orthologues are present in pro- and eu-
karyotes. The SLC13A family members contain numerous predicted
consensus phosphorylation and N-myristoylation sites with unknown
functional signiﬁcance. A highly conserved consensus sequence motif is
present in each of the ﬁve family members (Markovich, 2001). Mam-
malian SLC13A sodium-coupled cotransporters are located in the
plasma membrane of epithelial cells with ubiquitous expression, but
primarily in liver, kidney, small intestine, placenta and the central
nervous system. All the mammalian transporters are electrogenic with a
general sodium:substrate ratio of 3:1 or 4:1. The SLC13A family
members are functionally divided into two groups: SLC13A1 and
SLC13A4 belong to the sodium-sulfate cotransporters (NaS) mainly
transporting sulfate, selenate and thiosulfate whereas SLC13A2,
SLC13A3 and SLC13A5 are sodium- di and tri-carboxylate co-
transporters (NaDC) carrying Krebs-cycle intermediates such as citrate,
succinate, and α-ketoglutarate (Willmes & Birkenfeld, 2013) (Table 1).
The bacterial INDY homolog protein binds one molecule of citrate
and one molecule of sodium. Conserved amino acids, serving as the
structural basis for the transporter speciﬁcity, are found over a wide
range of species (Mancusso, Gregorio, Liu, & Wang, 2012). The so-
dium:citrate stoichiometry for mINDY is 4:1, which is in contrast to the
other SLC13 family members. In humans, the mIndy gene is located on
chromosome 17p13 with a size of approximately 30 kb containing 12
exons (Inoue, Zhuang, & Ganapathy, 2002). A number of common
splice variants have been documented in the human EST database,
especially in the liver. A splice variant lacking 43 N-terminal residues
has previously been reported, but function and speciﬁc tissue dis-
tribution are still unknown (Pajor, 2006). Another common splice
variant for mIndy, that is found at> 30% abundance in the mRNA of
liver, leaves out one of the exons, resulting in a shorter mINDY protein,
lacking the entire 10th membrane domain, and is predicted to be
functionally inactive (NCBI database). Given mINDY's dimeric nature, a
non-functional protein could conceivably dimerize with the normal
protein. A dominant negative eﬀect on mINDY cellular activity may
ensue. mINDY has high substrate speciﬁcity for the tricarboxylate ci-
trate, and exhibits the inward electrogenic sodium-coupled substrate
cotransport. Moreover, mINDY mediated citrate transport appears to be
pH-sensitive. Maximal activity is exhibited at pH 7.0–7.5 and the
transporter is inhibited at acidic and alkaline pH (Inoue et al., 2004).
The transporter shows lower aﬃnities to other Krebs-cycle inter-
mediates such as succinate, malate or fumarate (Inoue, Zhuang, &
Ganapathy, 2002; Inoue, Zhuang, Maddox, et al., 2002; Inoue et al.,
2004). mINDY is less selective to other organic anions. For example,
mINDY does not mediate the uptake of glutarate derivates into neurons
(Brauburger, Burckhardt, & Burckhardt, 2011). Interestingly, mINDY is
lithium-sensitive with substantial quantitative and qualitative species
diﬀerences. Human mINDY is stimulated by lithium although INDY is
inhibited or unaﬀected in most other species (Gopal et al., 2015; Inoue,
Zhuang, Maddox, Smith, & Ganapathy, 2003).
Several homology models of human SLC13 family members, NaDC1,
NaDC3, and mINDY/NaCT, were recently reported in the literature
(Colas, Pajor, & Schlessinger, 2015; Colas, Schlessinger, & Pajor, 2017;
Mancusso et al., 2012; Mulligan et al., 2016; Nie, Stark, Symersky,
Table 1
Overview of the human, mouse and rat SLC13A family members.
Name Synonym Expression Substrate Reference
Slc13a1 NaS1, NaSi-1 Human: kidney
Mouse: kidney, ileum, duodenum/jejunum and
colon, caecum, testis, adrenal, adipose tissue
Rat: kidney, small intestine
Sulfate, thiosulfate,
selenate
Markovich (2000), Busch et al. (1994), Markovich and Murer
(2004) and Markovich, Forgo, Stange, Biber, and Murer (1993)
Slc13a2 NaDC1, NaC1,
SDCT1
Human: kidney, intestine
Mouse: kidney, intestine
Rat: small intestine, large intestine, kidney,
liver, lung, epididymis
Succinate, α-ketoglutarate
citrate
Chen, Shayakul, Berger, Tian, and Hediger (1998), Pajor, Sun, and
Valmonte (1998) and Pajor and Sun (2000)
Slc13a3 NaDC3, NaC3,
SDCT2
Human: brain, kidney, placenta, liver, pancreas,
eye
Mouse: kidney, brain
Rat: kidney, liver, brain, placenta
Succinate, α-ketoglutarate,
citrate
Chen, Tsukaguchi, Chen, Berger, and Hediger (1999), Kekuda et al.
(1999), Pajor, Gangula, and Yao (2001) and Wang et al. (2000)
Slc13a4 NaS2, SUT-1 Mouse: placenta, brain, lung, eye, heart, testis,
thymus, liver
Human: placenta, brain, heart, testis, thymus,
liver
Rat: placenta, brain, liver
Sulfate Dawson et al. (2005), Dawson et al., 2006 and Markovich, Regeer,
Kunzelmann, and Dawson (2005)
Slc13a5 NACT, INDY Human: liver, testis, brain, (kidney, heart)
Mouse: liver, brain, testis
Rat: liver, testis, brain
Citrate, succinate, malate
fumarate
Inoue, Zhuang, and Ganapathy (2002), Inoue, Zhuang, Maddox,
Smith, and Ganapathy (2002) and (Gopal et al., 2007
D.M. Willmes et al. Pharmacology and Therapeutics 185 (2018) 1–11
2
Kaplan, & Lu, 2017; Pajor et al., 2016; Schlessinger, Sun, Colas, & Pajor,
2014). These models were constructed based on the crystal structure of
bacterial INDY (VcINDY, PDB code 4F35) used as a template (Mancusso
et al., 2012).
To understand human mINDY/NaCT's transport mechanism we
propose a new human mINDY/NaCT homology model (Fig. 1). Pub-
lished homology model and crystal structure of the VcINDY were used
to create in-silico models of inward and outward conformations of
human NaCT, referred to as NaCTinward and NaCToutward respectively.
The NaCTinward model was based on the crystal structure of VcINDY's
inward conformation (PDB code 4F35). The NaCToutward model was
based on VcINDY's homology model in outward conformation as re-
ported by Schlessinger et al. (2014).
Structural comparison between NaCTinward and NaCToutward sug-
gests signiﬁcant secondary structure transformation between both
conformations during the transport process, as was recently observed
for VcINDY (Pajor, 2014). In the proposed mechanism, two central
helical hairpins called HPout and HPin (Fig. 1) act as inner and outer
gates covering the substrate-binding site while regulating substrate
binding and release. In NaCT these hairpins contain conserved residues
that are essential for citrate binding, including motives SNT in HPin
(residues: S140, N141 and T142) and SNV in HPout (residues: S464,
N465 and V466). These observations are consistent with the SDM data
performed for VcINDY on similar conserved residues (Pajor, 2014). The
conformational change of these hairpins between mINDY/NaCTinward
and mINDY/NaCToutward has a direct eﬀect on the NaCT-citrate aﬃnity
and therefore on substrate binding and release from the transporter. For
this reason, restricting the protein ﬂexibility in this region can have
signiﬁcant eﬀects on the rate of substrate transport.
Furthermore, residues G228, V231, V232 and G409, aﬀect both,
citrate transport and inhibition (Pajor et al., 2016). Intriguingly, re-
sidues Q77 and T86, located outside of the putative citrate binding site,
were also involved in mINDY/NaCT inhibition. These ﬁndings may
suggest alternative ligand binding sites. Further exploration of mINDY/
NaCTinward and mINDY/NaCToutward surface topology oﬀers that these
alternative binding sites could be used for the discovery of allosteric
mINDY/NaCT inhibitors. These data provide important insights into the
mechanism of transport and inhibition in mINDY/NaCT and can be
applied to guide structure-based drug design of new generation of
mINDY/NaCT inhibitors.
3. Metabolic actions of citrate
Citrate, as the substrate with highest aﬃnity to mINDY/NaCT, is a
key metabolite involved in intracellular signaling as it coordinates
glycolysis and lipid synthesis pathways. Citrate inhibits phospho-
fructokinase (PFK) by allosteric modulation, thereby reducing glyco-
lytic ﬂux (Ros & Schulze, 2013). Furthermore, citrate promotes poly-
merization and, thus, activation of acetyl CoA carboxylase (ACC),
which catalyzes the rate limiting step in de novo lipogenesis (Gregolin,
Ryder, Kleinschmidt, Warner, & Lane, 1966; Huard et al., 2015). Ad-
ditionally, citrate has been reported to stimulate gluconeogenesis
through fructose 1,6 bisphosphatase (F1,6BPase) activation (Fu &
Kemp, 1973; Nielsen, 1983). Citrate, as a tricarboxylic acid (TCA) in-
termediate is involved in the generation of biochemical energy in the
form of adenosine triphosphate (ATP) from acetyl-CoAs derived from
carbohydrates and fatty acids. In addition, the TCA cycle provides
precursors of certain amino acids as well as the reducing agent NADH
that is required for numerous other biochemical reactions.
Cytosolic citrate is known as the prime carbon source for synthesis
of fatty acids, triacylglycerols, cholesterols and low-density lipopro-
teins. Moreover, citrate activates fatty acid synthesis and aﬀects glu-
coneogenesis and β-oxidation (Bloch & Vance, 1977; Ruderman, Saha,
Vavvas, & Witters, 1999; Spencer & Lowenstein, 1962). Major organs
involved in lipogenesis are the liver and white adipose tissue. Lipo-
genesis directly correlates with cytosolic citrate concentrations, in part
through direct import across the plasma membrane by mINDY/NaCT
(Gopal et al., 2007; Inoue, Zhuang, & Ganapathy, 2002). Fig. 2 shows
the cellular fate of citrate in hepatocytes.
Serum citrate concentration is relatively constant, ranging from 50
to 200 μM (Nielsen, 1983; Nielsen & Sorensen, 1981; Nielsen &
Thomsen, 1979). While the Kt value of rat mINDY is around
18 ± 4 μM, the Kt value of 604 ± 73 μM is much higher for human
mINDY/NaCT (Inoue, Zhuang, & Ganapathy, 2002; Inoue, Zhuang,
Maddox, et al., 2002). Since physiological citrate concentrations in
human circulation range around 135 μM, we and others showed that
the human transporter is hardly saturated under physiological condi-
tions, such that human mINDY/NaCT is a transporter with a low aﬃnity
but high capacity (Km = 2254 ± 207 μM, Vmax = 25,117 ±
1051[pmol/mg·min−1]) whereas mouse mINDY has high aﬃnity but
lower capacity for citrate (Km = 49 ± 9 mM, Vmax = 3760 ± 160
Fig. 1. Homology model of human mINDY/NaCToutward (modelled with the homology modeling tool as implemented in the MOE software package (Chemical Computing Group, version
2016.08) — side-view). The backbone of NaCT is represented as a ribbon when the subunit A is colored in dark green and subunit B in blue, HPout and HPin in monomer A are yellow and
pink respectively. The carbon and oxygen atoms of citrate are colored green and red respectively when the atom of sodium is shown as an orange sphere. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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[pmol/(mg·min)]). Citrate absorption from nutritional sources in the
small intestine seems to be mediated mainly via NaDC1 and NaDC3
(Fegan, Khan, Poindexter, & Pak, 1992; Pajor, 2014). More than 90% of
an oral citrate load can be absorbed by this mechanism and ameliorate
hypocitraturia (Fegan et al., 1992; Rudman et al., 1980). At physiolo-
gical pH, most of the serum citrate circulates in the form of triply
charged citrate bound to divalent ions, such as calcium and magnesium,
and is ﬁltered freely in renal glomeruli; reabsorption takes place pre-
dominantly in the proximal renal tubule via NaDC1 (Pajor, 2014).
Moreover citrate is also taken up into the kidney by removal from post
glomerular blood. Similarly to our ﬁndings in the liver, citrate is oxi-
dized by the TCA cycle in the kidney and metabolized to glucose by
gluconeogenesis (Baruch, Burich, Eun, & King, 1975; Nielsen, 1983;
Nieth & Schollmeyer, 1966; Pashley & Cohen, 1973). Citrate is also
taken up by the liver via mINDY/NaCT and NaDC3. In the liver, citrate
can be oxidized or it can serve as substrate for fatty acid synthesis and
gluconeogenesis (Neuschafer-Rube et al., 2014). Circulating citrate is
released from muscle, adipose tissue, skin and bone. Citrate con-
centrations in bone exceed that of most other tissues and account for
70% of total body citrate content (Dickens, 1941). The source of citrate
in bone is controversial. One study identiﬁed mIndy in bone matrix and
proposed that citrate can be taken up into the bone from plasma, being
deposited in the mineral fraction (Dickens, 1941; Irizarry et al., 2017;
Liu et al., 2009). Other studies did not detect mIndy expression in os-
teoblasts. Instead, osteoblasts produced citrate on their own through m-
aconitase inhibition thereby accumulating TCA borne citrate in-
tracellularly (Costello, Franklin, Reynolds, & Chellaiah, 2012; Franklin,
Chellaiah, Zou, Reynolds, & Costello, 2014). The authors proposed that
osteoblasts are capable of de novo citrate production necessary for bone
formation and that this mechanism helps to maintain plasma citrate
levels (Franklin et al., 2014).
Skeletal muscle, with its high capacity for oxidative substrate uti-
lization appears to be an important source of citrate released to the
plasma pool. The isolated rat hindquarter releases considerable citrate
amounts (Lee & Davis, 1979). The femoral arterio-venous plasma ci-
trate diﬀerence is largely negative in a physically active individual.
Thus, the working skeletal muscle is considered a major source of
plasma citrate during exercise (Nielsen & Thomsen, 1979). Moreover,
the human heart releases citrate and it has been postulated that this
function, similarly to liver and kidney, may contribute to the regulation
of myocardial lipid and glucose metabolism (Nielsen, Henningsen,
Bagger, Thomsen, & Eyjolfsson, 1980). The physiological signiﬁcance of
plasma citrate homeostasis is largely unknown. Citrate's plasma half-life
in dogs is about 20 min. Estimates in man suggest citrate turnover rates
around 250 μmol/h/L in man with a tissue to plasma gradient of 3–4 to
1 (Nielsen, 1983). Citrate, which is absorbed externally, is oxidized to a
major extent, and may contribute to furnishing cellular energy needs.
Signiﬁcant circadian rhythmicity is observed for citrate concentrations,
peaking in the postprandial phase. This pattern seems to be disturbed in
type 1 diabetes (Nielsen & Sorensen, 1981; Thomassen et al., 1981). In
patients with type 1 diabetes, insulin decreases circulating citrate le-
vels. Prolonged fasting also reduces citrate levels in humans. Moreover,
we have shown, that glucagon increases the expression of mIndy via the
transcription factor CREB in rats, and by this mechanism, increases the
uptake of citrate into the liver in early fasting (Neuschafer-Rube et al.,
2014).
It is suggested that transcriptional regulation of mIndy responds to
the nutritional state, thus, implicating metabolic factors. For example,
caloric restriction increases Indy homolog expression in Bicyclus any-
nana butterﬂies, whereas Indy expression is reduced by caloric re-
striction in D. melanogaster (Pijpe, Pul, van Duijn, Brakeﬁeld, & Zwaan,
2011; Wang et al., 2009). In mice, 36 hour fasting reduces mIndy ex-
pression in the liver (Birkenfeld et al., 2011). In contrast, gavaging large
amounts of olive oil, strongly induced hepatic mIndy expression in rats,
as identiﬁed by microarray assays (Martinez-Beamonte et al., 2011).
Apparently, mIndy expression is also aﬀected by epigenetic
Fig. 2. Cellular fate of extracellular citrate entering the cell via mINDY and mitochondrial citrate entering the cytosol from the TCA cycle.
(Na = sodium; TG = triglyceride; CoA = coenzyme A; ACC = acetyl CoA carboxylase; Acly = ATP citrate lyase; OAA = oxaloacetic acid; FATP = fatty acid transport protein;
NEFA = non esteriﬁed fatty acids; STAT = signal transducer and activator of transcription; CIC = citrate carrier; TCA = tricarboxylic acid cycle; IL-6 = interleukin 6).
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mechanisms. Proﬁles of whole genome integrative methylation and
gene expression analysis in glioblastoma patients demonstrated an in-
verse correlation between promoter methylation and mIndy expression
level in glioblastomas. In this setting, mIndy was downregulated with
hypermethylation of its promoter (Etcheverry et al., 2010). In renal cell
cancer samples, hypermethylation of a gene cluster including mIndy
was associated with poor clinical outcomes (Tian et al., 2014). A recent
study analyzed placentas and cord blood of term infants born small for
gestational age. The authors observed mIndy hypermethylation to-
gether with downregulation of the mINDY/NaCT protein. Children with
reduced mIndy expression had reduced circulating IGF-1 levels as well
as decreased total and abdominal fat stores at an age of two weeks (Diaz
et al., 2016).
4. Proposed metabolic and life span extending function
Indy ﬁrst came to the attention of the general scientiﬁc community
when it was demonstrated that mutations in the Indy gene are asso-
ciated with lower body fat content, insulin-like proteins and reactive
oxygen species leading to lifespan extension by mechanisms resembling
caloric restriction in most (Neretti et al., 2009; Rogina et al., 2000;
Wang et al., 2009) but not all studies (Toivonen et al., 2007). In D.
melanogaster, INDY preferentially transports citrate and succinate across
the plasma membrane. The transporter also shows aﬃnity for alpha-
ketoglutarate and fumarate. Fly Indy is mainly expressed in tissues in-
volved in energy homeostasis, is found at lower levels in the nervous
system, and encodes an electroneutral tricarboxylate carrier. Interest-
ingly, Indy mRNA is down-regulated in dietary restricted healthy D.
melanogaster. Moreover, Indy mutated long-lived D. melanogaster share
several phenotypes with long-lived caloric restricted ﬂies. Food intake
was not reduced in Indy mutant long-lived ﬂies and fertility was normal
(Inoue, Zhuang, & Ganapathy, 2002; Mancusso et al., 2012; Neretti
et al., 2009; Rogers & Rogina, 2014; Rogina et al., 2000; Rogina &
Helfand, 2013; Wang et al., 2009; Willmes & Birkenfeld, 2013; Willmes,
Helfand, & Birkenfeld, 2016).
Likewise, knockdown of the Indy homolog CeNac2 in C. elegans
extended life span, an eﬀect mediated partly via AMPK/aak2 (Fei et al.,
2004; Schwarz et al., 2015). C. elegans with reduced Indy expression
exhibited lower lipid content, as shown by two independent groups,
while one group failed to observe this phenotype (Fei et al., 2004;
Schwarz et al., 2015; Toivonen et al., 2007). The C. elegans Indy
homolog CeNac2 is expressed mainly in tissues functioning as sites of
nutrient absorption and fat storage (Fei, Inoue, & Ganapathy, 2003;
Knauf, Rogina, Jiang, Aronson, & Helfand, 2002; Wang et al., 2009).
CeNac2 is also located on the plasma membrane and transports TCA
cycle intermediates, which are used to generate biochemical energy in
the form of ATP.
The cloning of mIndy demonstrated that substrate transport via
mINDY is, in contrast to ﬂies, sodium dependent (Inoue, Zhuang, &
Ganapathy, 2002). mINDY mediates the cotransport of citrate, succi-
nate and other dicarboxylates together with sodium across the plasma
membrane in an electrogenic manner, coupling three to four sodium
ions to the transport of each divalent anion substrate (Birkenfeld et al.,
2011; Gopal et al., 2007; Inoue, Zhuang, Maddox, et al., 2002; Pajor,
1996, 2006). The transport process for cellular citrate uptake is several
times more selective than for other TCA cycle intermediates (Inoue,
Zhuang, Maddox, et al., 2002). mINDY shows a highly conserved amino
acid sequence of the N-terminal sodium and carboxy-binding motif
between many species and is highly expressed in the liver and moder-
ately in brain, testis and kidney (Inoue, Zhuang, & Ganapathy, 2002;
Inoue, Zhuang, Maddox, et al., 2002; Mancusso et al., 2012; von
Loeﬀelholz, Docke, et al., 2017).
Genetic whole-body mIndy deletion in mice produced a metabolic
phenotype with striking similarities to caloric restriction. Moreover, the
gene deletion protected mice from high fat diet (HFD) induced obesity,
hepatic steatosis, and insulin resistance. mINDY knockout mice showed
increased energy expenditure, improved hepatic mitochondrial bio-
genesis, enhanced hepatic fatty acid oxidation and reduced hepatic
lipid synthesis (Birkenfeld et al., 2011). mINDY knockout mice dis-
played reduced uptake of citrate from the circulation in the liver, but
not kidney and adipose tissue, concomitant with elevated circulating
citrate levels (Birkenfeld et al., 2011; Shulman & Helfand, 2011). Body
weight gain with age was also reduced with mINDY deletion. Un-
expectedly, oxygen consumption, carbon dioxide production and en-
ergy expenditure were increased. In parallel, an elevated hepatic mi-
tochondrial density and increased gene expression of the peroxisome-
proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1α)
were observed in the livers of mINDY knockout mice. The liver of
mINDY knockout mice share approximately 80% similar transcriptional
changes, including the expression of electron transport chain compo-
nents, with caloric restricted mice, as shown by microarray studies.
Hepatic triglyceride level and liver lipid deposits were lower in mIndy
deleted mice. Lipid oxidation was increased and citrate incorporation
into fatty acids and sterols was reduced in livers of diet-induced mINDY
knockout mice. The ﬁndings are consistent with elevated lipid oxida-
tion and reduced lipid synthesis upon mIndy deletion in obese mice
(Birkenfeld et al., 2011; Willmes & Birkenfeld, 2013).
In rat primary hepatocytes, mIndy expression and [14C]-citrate up-
take was induced by physiological concentrations of glucagon via a
cAMP-dependent mechanism through a conﬁrmed cAMP responsive
element binding protein (CREB) binding site within the mIndy pro-
motor (Neuschafer-Rube et al., 2014). The rat mIndy promoter se-
quence located upstream of the most frequent transcription start site
was determined by 5′-rapid ampliﬁcation of cDNA ends. In silico ana-
lysis identiﬁed a CREB-binding site within the promoter fragment of
mIndy. Functional relevance for the CREB-binding site was demon-
strated by reporter gene constructs that were induced by CREB acti-
vation when under the control of a fragment of a wildtype promoter,
whereas promoter activity was lost after site-directed mutagenesis of
the CREB-binding site. Moreover, CREB binding to this promoter ele-
ment was conﬁrmed by chromatin immunoprecipitation in rat liver. In
vivo studies revealed that mIndy was induced in livers of fasted as well
as in high fat-diet streptozotocin diabetic rats, in which CREB is con-
stitutively activated. mIndy induction was completely prevented when
CREB was depleted by antisense oligonucleotides. These data suggest
that mIndy is a CREB-dependent glucagon target gene that is induced in
fasting and in type 2 diabetes (Neuschafer-Rube et al., 2014). In line
with these results, mIndy siRNA-mediated knockdown reduced overall
lipid content in the stable human hepatocarcinoma cell line HepG2 (Li
et al., 2015).
Diet-induced hepatic steatosis is enhanced by arylhyrocarbon re-
ceptor (AhR) activation, both, in humans and animal models
(Neuschafer-Rube et al., 2015). Benzo[a]pyrene induced mIndy ex-
pression in primary rat hepatocytes in an AhR-dependent manner. The
induction resulted in an increased citrate uptake and citrate in-
corporation into lipids which were probably enhanced by the benzo[a]
pyrene-dependent induction of key enzymes of fatty acid synthesis. A
potential AhR binding site in the rat mIndy promoter appears to be
conserved in the human promoter. Elimination or mutation of this site
largely abolished the activation of the mIndy promoter by benzo[a]
pyrene. This study thus identiﬁed mIndy as a AhR target gene
(Neuschafer-Rube et al., 2015).
Very recently, interleukin-6 was shown to regulate mIndy by
binding to its cognate receptor (von Loeﬀelholz, Docke, et al., 2017). In
obese, insulin-resistant patients with NAFLD, hepatic mIndy expression
was increased and mIndy gene expression was independently associated
with hepatic steatosis. In non-human primates, a two-year westernized
diet also increased hepatic mIndy expression. Liver microarray studies
in non-human primates showed an association of high mIndy gene ex-
pression levels and pathways involved in hepatic lipid metabolism and
immunological processes. Studies in human primary hepatocytes con-
ﬁrmed that IL-6 markedly induced mIndy transcription via the IL-6-
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receptor and activation of the transcription factor Stat3 and a putative
start site of the human mIndy promotor was determined. Activation of
the IL-6/Stat3 pathway stimulated mIndy expression, enhanced cyto-
plasmic citrate inﬂux and augmented hepatic lipogenesis in vivo
whereas deletion of mIndy completely prevented the stimulating eﬀect
of IL-6 (von Loeﬀelholz, Docke, et al., 2017).
mINDY mediates cellular citrate uptake, which plays important
roles in the de novo fatty acid and cholesterol synthesis. The pregnane X
receptor (PXR, NR1I2), which was initially characterized as a xeno-
biotic sensor, has been functionally linked to the regulation of various
physiologic processes associated with lipid metabolism and energy
homeostasis. The mIndy gene is also a transcriptional PXR target (Li
et al., 2015). mIndy mRNA and protein expression were markedly in-
duced by the prototypical PXR activator rifampicin in human primary
hepatocytes. Two enhancer modules located upstream of the mIndy
gene transcription start site, that are associated with regulation of PXR-
mediated mIndy induction were characterized by cell-based luciferase
reporter assays, electrophoretic mobility shift assays, and chromatin
immunoprecipitation assays. Further functional analysis revealed that
rifampicin can enhance lipid accumulation in human primary hepato-
cytes, and knockdown of mIndy expression alone leads to a signiﬁcant
decrease of the lipid content in HepG2 cells. Overall, these results re-
vealed mIndy as a novel target gene of PXR and may contribute to drug-
induced steatosis and metabolic disease in humans.
Low weight at birth is associated with subsequent susceptibility to
diabetes. A genome-wide DNA methylation analysis in placentas of
term infants born appropriate-for-gestational-age (AGA) or small-for-
gestational-age (SGA) was performed and analyzed in cord blood to
identify new genes related to fetal growth and neonatal body compo-
sition (Diaz et al., 2016). mIndy was downregulated and hypermethy-
lated in both, SGA placenta and cord blood. SGA infants have less
adipose and are more insulin sensitive than AGA infants (de Zegher
et al., 2013). These data suggest that reduced mIndy expression may be
a programming mechanism attempting to protect those fetuses from
excessive fat accumulation and impaired insulin action (Diaz et al.,
2016).
5. Role of INDY in metabolic disease and related disorders
5.1. Interaction between NAFLD, insulin resistance and obesity
Non-alcoholic fatty liver disease (NAFLD), central obesity and in-
sulin resistance are closely linked to each other, which is highlighted by
the fact that obese subjects and patients with type 2 diabetes are often
aﬀected by NAFLD (Birkenfeld & Shulman, 2014; Gaggini et al., 2013;
Gastaldelli et al., 2007; Yang, Hung, et al., 2016). The condition is
deﬁned as the presence of cytoplasmic lipid droplets in> 5% of he-
patocytes or triglyceride levels exceeding the 95th percentile for lean,
healthy individuals in the absence of signiﬁcant alcohol consumption or
viral and autoimmune liver disease. Moreover, patients with NAFLD are
at increased risk for cardio-metabolic complications such as type 2
diabetes (T2DM) and cardiovascular disease in addition to hepatic
complications (Amaro et al., 2010; Bhatia, Curzen, Calder, & Byrne,
2012; Chalasani et al., 2012; Gastaldelli et al., 2007; Kantartzis,
Machicao, et al., 2009, Kantartzis, Peter, et al., 2009; Monetti et al.,
2007; Sevastianova et al., 2011; Targher et al., 2007; Visser et al.,
2011). NAFLD is a chronic condition ranging from relatively benign
steatosis to more signiﬁcant liver injury including cirrhosis and hepa-
tocellular carcinoma. Histology may show lobular inﬂammation, he-
patocyte swelling, ﬁbrosis and overt cirrhosis like for example in non-
alcoholic steatohepatitis (NASH) (Browning et al., 2004; Day, 2002;
Nati et al., 2016; Szczepaniak et al., 1999). Insulin resistance is a
characteristic feature of NAFLD, even when subjects are not obese
(Bugianesi et al., 2005; Sanyal et al., 2001; Stefan, Schick, & Haring,
2017; Yki-Jarvinen, 2010).
Increased lipid species, such as diacylglycerols and ceramides
interact directly with the insulin signaling cascade in the liver. While
DAGs activate novel protein kinase ε, phosphorylating Thr1160 on the
insulin receptor, ceramides inhibit AKT (Petersen et al., 2016; Turpin
et al., 2014). Together, these mechanisms promote hepatic insulin re-
sistance. However, insulin resistant subjects with NAFLD also show
reduced insulin sensitivity in skeletal muscle and adipose tissue
(Bugianesi et al., 2005; Gastaldelli et al., 2007; Lomonaco et al., 2012).
Indeed, adipose tissue becomes resistant to insulin's antilipolytic ac-
tions. Therefore, free fatty acid (FFA) release is increased, despite an
increase in, both, hepatic and systemic lipid oxidation. Increased FFA
availability promotes VLDL-TG secretion (Arner, 2002; Miles & Nelson,
2007; von Loeﬀelholz, Lieske, et al., 2017). FFA are taken up by tissues
for oxidation and accumulate as ectopic fat (Bugianesi et al., 2005;
Hwang et al., 2007; Machado et al., 2012). Possibly, ectopic fat could
serve as a defense mechanism against lipotoxicity and individuals with
NAFLD could develop NASH and cirrhosis as a consequence of a second
hit elicited through inﬂammation and excess reactive oxygen species
(Choi & Diehl, 2008; Day, 2002; Neuschwander-Tetri, 2010). Moreover,
adaptation of mitochondrial energetics, gene expression, morphology,
and content appear to play a key role in the transition from steatosis to
full blown NASH (Patterson et al., 2016; Satapati et al., 2012; Sunny,
Parks, Browning, & Burgess, 2011; Sunny, Bril, & Cusi, 2017; Yang, He,
et al., 2016). Finally, the ﬁbrosis associated with NASH may progress to
hepatic cirrhosis predisposing patients to hepatocellular carcinoma.
Therefore, preventing NAFLD, NASH and hepatic cirrhosis also protects
against malignant liver disease (De Minicis, Marzioni, Benedetti, &
Svegliati-Baroni, 2013; Li et al., 2017).
5.2. Indy in metabolic disease
In the last few years, genetic mINDY deletion and pharmacological
mINDY inhibition was shown to ameliorate NAFLD, obesity and insulin
resistance in model organisms (Birkenfeld et al., 2011; Neuschafer-
Rube et al., 2014; von Loeﬀelholz, Docke, et al., 2017; Willmes et al.,
2016; Willmes & Birkenfeld, 2013). Therefore, mNDY has been pro-
posed to be an ‘ideal target for the treatment of metabolic diseases’
(Birkenfeld et al., 2011; Brachs et al., 2016; Neretti et al., 2009;
Neuschafer-Rube et al., 2014; Pesta et al., 2015; Rogina, 2017; Schwarz
et al., 2015; Shulman & Helfand, 2011; von Loeﬀelholz, Docke, et al.,
2017; Willmes et al., 2016; Willmes & Birkenfeld, 2013).
Whole body deletion of mINDY in mice protected them from high
fat diet and age-related insulin resistance, NAFLD and obesity. The
phenotype was mediated by reduced hepatic de novo lipogenesis along
with increased hepatic lipid oxidation, improved mitochondrial lipid
oxidation and AMPK activation. However, this approach did not mimic
a therapeutic setting.
The impact of a selective inducible hepatic knockdown of mIndy on
whole body lipid and glucose metabolism using 2′-O-methoxyethyl
chimeric anti-sense oligonucleotides (ASOs) in high fat fed rats was
examined in a preventive setting at the onset of HFD feeding. A 4-week
ASO treatment reduced mIndy mRNA expression by 91%. The ASO
treated and control rats had similar body weights. Yet, the ASO-induced
mIndy reduction led to a 74% reduction in fasting plasma insulin
concentrations and a 35% reduction of plasma triglycerides.
Additionally, hepatic triglyceride content was reduced by the ASO
mIndy knockdown, likely mediating a trend to decreased basal rates of
endogenous glucose production and an increased suppression of hepatic
glucose production during a hyperinsulinemic-euglycemic clamp (Pesta
et al., 2015). Together, these data corroborate the mIndy KO phenotype
of improvements in hepatic glucose production, insulin responsiveness
and protection from NAFLD.
Independently, another study conﬁrmed that knockdown of hepatic
mIndy expression by a liver-selective siRNA resulted in> 60% mIndy
knockdown, improved insulin sensitivity in a hyperinsulinemic-eu-
glycemic clamp and prevented triglyceride accumulation in the liver,
independent of changes in body weight (Brachs et al., 2016).
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Protection from NAFLD and insulin resistance might also prevent
NASH, cirrhosis and hepatocellular carcinoma. Along these lines, RNAi-
mediated silencing of INDY expression in the human hepatoma cell
lines HepG2 and Huh7 suppressed cell proliferation, colony formation
and induced cell cycle arrest. The mechanism seems to be mediated via
metabolic actions: mIndy knockdown in HepG2 and Huh7 cells led to
reductions in intracellular citrate concentrations, the ATP/ADP ratio,
phospholipid content, and ATP citrate lyase expression (Li et al., 2017).
These ﬁndings conﬁrm observations in mINDY knockout mice
(Birkenfeld et al., 2011). Moreover, in vitro and in vivo assays demon-
strated that mIndy depletion promoted AMPK activation. The response
was accompanied by deactivation of the oncogenic mechanistic target
of rapamycin signaling mTOR. Together, these data show, that mIndy
by regulating hepatic energy homeostasis, also aﬀects ﬁbrotic and on-
cogenic pathways (Li et al., 2017). Indeed, obese patients with NAFLD
exhibited increased mIndy expression compared with lean individuals
with normal hepatic lipid content. However, the above mentioned
studies do not deﬁnitively demonstrate the concept that mINDY/NaCT
inhibition is eﬀective in treating type 2 diabetes and NAFLD (von
Loeﬀelholz, Lieske, et al., 2017).
Proof of concept could be provided by using mINDY/NaCT in-
hibitors. Small mINDY inhibitor molecules have been identiﬁed via
virtual docking using a homology model of the plasma membrane
transporter and a proteoliposome-based assay to measure their in-
hibitory activity on citrate transport (< 73% inhibition at 1 mM) (Sun
et al., 2010). Inhibitors of NaDC1 and NaDC3 weakly inhibited mINDY
in transfected CUBS cells (Pajor & Randolph, 2007). However, these
compounds exhibited cytotoxicity in HEK-293-derived cell-based assays
thereby confounding the interpretation of citrate uptake data (Huard
et al., 2015). Moreover, previously reported mINDY inhibitors dis-
played poor ADME (absorption, distribution, metabolism, excretion)
properties precluding their use in in vivo experiments (Sun et al., 2010).
Better suited for a proof of concept study was the following com-
pound: this novel small dicarboxylate molecule (compound 2 or PF-
06649298) selectively and potently inhibited citrate transport through
mINDY/NaCT, both in vitro and in vivo (Huard et al., 2015). Binding and
transport experiments indicated that compound 2, which was dis-
covered using a substrate-based design strategy, speciﬁcally binds to
mINDY in a competitive and stereosensitive manner, and is, itself, a
substrate for mINDY transport. The favorable pharmacokinetic prop-
erties of compound 2 permitted in vivo experiments to evaluate the
eﬀect of inhibiting hepatic citrate uptake on metabolic endpoints. Mice
were fed a high fat diet for 12 weeks and subsequently treated with
either 250 mg/kg of compound 2 or vehicle twice a day for three weeks.
Glucose intolerance on high fat diet was completely reversed in mice
treated with compound 2 during an oral glucose tolerance test. Further,
livers of treated mice tended to exhibit lower hepatic di- and trigly-
cerides, with higher levels of acylcarnitine. The ﬁnding may indicate
greater ﬂux through β-oxidation pathways and was corroborated by a
trend for increased β-hydroxybutarate concentrations. Subsequently,
molecular modeling and site-directed mutagenesis of human mINDY,
transport characterization and cell-surface biotinylation were applied
to examine the residues involved in inhibitor binding and transport
(Pajor et al., 2016). The results indicate that residues located near the
putative citrate binding site (G228, V231, V232, and G409) aﬀect both
citrate transport and inhibition of citrate uptake by compounds 2 and 4.
V231 appears to distinguish between compounds 2 and 4 as inhibitors.
Furthermore, residues located outside the putative citrate binding site
(Q77 and T86) may also play a role in mINDY/NaCT inhibition by
compounds 2 and 4. These results provide new insight into the me-
chanism of transport and inhibition of mINDY/NaCT and supply a basis
for future drug design of SLC13 inhibitors (Pajor et al., 2016). Another
compound 4a, which is less selective, was published recently (Huard
et al., 2016). Treatment with 4a reduced citrate uptake in liver, kidney
and testis of rodents resulting in modest improvement of glucose me-
tabolism. However, compound 4a shows only partial selectivity for
mINDY, over NaDC1 and NaDC3 and additionally increased citrate
concentrations in plasma and urine (Huard et al., 2016).
Recently, the pharmacology of these newly identiﬁed mINDY/NaCT
inhibitors compounds 2 and 4a was elucidated using a combination of
14C-citrate uptake, membrane potential assays, and electrophysiology.
In contrast to their previously proposed mechanism of action, both
compounds 2 and 4a elicited allosteric, state-dependent mINDY/NaCT
inhibition with low-aﬃnity substrate activity in the absence of citrate.
As allosteric state-dependent modulators, the inhibitory potency of both
compounds appears to be highly dependent on the ambient citrate
concentration. Therefore, the detailed mechanism of action studies in
this publication may be of value in interpreting the in vivo eﬀects of
these compounds (Rives, Shaw, Zhu, Hinke, & Wickenden, 2016).
In pharmacokinetic studies, the unbound partition coeﬃcient (Kpuu)
was determined for a set of compounds from the SLC13A family that are
inhibitors and substrates of transporters in hepatocytes and in trans-
porter-transfected cell lines (Riccardi et al., 2016). Kpuu describes the
asymmetric free drug distribution of a compound between cells and
medium in vitro and plasma and tissue in vivo. Enantioselectivity was
observed, with (R)-enantiomers achieving much higher Kpuu than the
(S)-enantiomers in mIndy-transfected human embryonic 293 cells. The
intracellular free drug concentration correlated directly with in vitro
pharmacological activity rather than the nominal concentration in the
assay because of the high Kpuu mediated by mINDY/NaCT transporter
uptake.
Together, these data provide strong evidence for a role of mIndy in
the control of glucose and lipid metabolism in the liver and other tis-
sues. Through these mechanisms, mIndy may also aﬀect ﬁbrosis and
carcinogenesis. These ﬁndings were the basis for pharmacological in-
vestigations testing the therapeutic potential of mINDY/NaCT. In proof
of concept studies, small molecule inhibitors of mINDY/NaCT improved
glucose tolerance and fatty liver, conﬁrming genetic studies and further
strengthening the rationale for developing medications targeting
mINDY/NaCT in patients with insulin resistance and NAFLD. It will be
important to determine whether or not other conditions, such as NASH
and HCC can also be prevented or treated using this approach (Table 2).
6. Emerging relevance of Indy in neuronal metabolism
mIndy is expressed in the human brain, in neurons and possibly glia
of the mouse cerebral cortex, hippocampal formation, cerebellum and
olfactory bulb, and in neurons of the rat brain (Inoue et al., 2002; Pajor
et al., 2001; Wada, Shimada, & Fujita, 2006). In human glioblastoma
cells, mIndy was down-regulated suggesting that it may normally be
expressed in human glial cells (Bergeron, Clemencon, Hediger, &
Markovich, 2013; Etcheverry et al., 2010). In the cerebral cortex of rats,
mIndy expression is known to increase during postnatal development
and is much higher in the cerebral cortex of adult rats (Yodoya et al.,
2006).
The interest in the activity of mIndy and other plasma membrane
transporters of TCA cycle intermediates in the brain is driven in part by
knowledge that neurons do not express pyruvate carboxylase.
Therefore, neurons may not have the usual mechanisms for synthe-
sizing TCA intermediates and could require plasma membrane trans-
porters of TCA cycle intermediates to maintain normal metabolism
(Cesar & Hamprecht, 1995; Shank, Bennett, Freytag, & Campbell, 1985;
Yu, Drejer, Hertz, & Schousboe, 1983). Surprisingly normal neuronal
pyruvate carboxylation rates have been described that resemble those
seen in glial cells (Hassel, 2001; Hassel & Brathe, 2000a, 2000b). The
pathway by which neurons synthesize TCA cycle intermediates,
through carboxylation of pyruvate without pyruvate carboxylase, is not
yet understood. However, the fact that neurons can synthesize TCA
cycle intermediates de novo nevertheless indicates that the brain may
not critically depend upon transporters such as mINDY to maintain
normal metabolism.
Recently discovered mutations in the human mIndy/SLC13A5 gene
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have been linked to the development of early-onset epileptic en-
cephalopathy (Hardies et al., 2015; Thevenon et al., 2014). Aﬀected
individuals have subclinical seizures as early as the ﬁrst days of life
(Berg et al., 2010; Covanis, 2012). The mechanisms by which mutations
in SLC13A5 lead to severe seizure activity and the other accompanying
clinical signs are unknown (Bhutia, Kopel, Lawrence, Neugebauer, &
Ganapathy, 2017). Functional transport studies in vitro for over a dozen
diﬀerent mutations in SLC13A5 show little to no transport activity
(Hardies et al., 2015; Klotz, Porter, Colas, Schlessinger, & Pajor, 2016).
Interestingly, in a recent report from four aﬀected individuals, analysis
of patients' CSF samples revealed changes in multiple metabolites as-
sociated with carbohydrate metabolism, lipid synthesis and amino acid
pathways, such as beta-hydroxyisovaleroylcarnitine, an intermediate of
leucine metabolism and 2-methylcitrate and 3-hydroxybutyrate
(Bainbridge et al., 2017).
It is too early to draw a deﬁnitive conclusion as to whether and how
mIndy is involved in neuronal metabolism and whether modiﬁcations
in citrate-transporting function contribute to epileptic encephalopathy.
So far, mice with complete loss of mIndy activity do not exhibit a de-
leterious neurological phenotype, and as noted in earlier sections of this
review show various metabolic beneﬁts (Birkenfeld et al., 2011).
Clearly, more mechanistic studies are warranted to shed light on this
emerging aspect of mIndy.
7. Summary
An increasing wealth of data conﬁrm that ﬁndings gleaned from
lower organisms, such as D. melanogaster and C. elegans, can be trans-
lated into mammals as well as humans. Moreover, genetic data from
ﬂies, mice and rats show that deletion or reduction of mIndy gene
expression attenuates body fat, liver fat and/or insulin and glucose le-
vels. Most exciting is that recently identiﬁed chemical compounds that
inhibit mINDY/NaCT transport function have been shown to ameliorate
insulin resistance and NAFLD in mice. Since INDY expression is in-
creased in livers of obese humans with insulin resistance, it is tempting
to speculate that patients with type 2 diabetes and the metabolic syn-
drome could be treated with these or similar compounds in the future.
Apart from thiazolidinediones, which are rarely used in the treatment
of type 2 diabetes due to their side eﬀects, there are no other anti-
diabetic agents currently available that can simultaneously treat insulin
resistance and NAFLD. It will be of great interest in the future to see
whether mINDY inhibiting compounds will be amendable to ther-
apeutic interventions in patients. The ultimate question then will be
whether such a compound will also promote healthy aging and long-
evity.
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